Inhibition of the production of D2HG production by IDH1 mutation inhibitor ivosidenib or catabolism of D2HG by overexpression of D2HGDH may reverse D2HG induced muscle proteolysis and slow the progression of cancer cechexia. Here, IDH1 is linked to cancer.